Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells

Jayna J Mistry; Jamie A Moore; Prakritt Kumar; Christopher R Marlein; Charlotte Hellmich; Genevra Pillinger; Aisha Jibril; Federica Di Palma; Angela Collins; Kristian M Bowles; Stuart A Rushworth

doi:10.3324/haematol.2019.242974

Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells

Haematologica. 2021 Feb 1;106(2):589-592. doi: 10.3324/haematol.2019.242974.

Affiliations

¹ University of East Anglia, Norwich Medical School.
² Earlham Institute.
³ Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / metabolism
Mesenchymal Stem Cells* / metabolism
Mitochondria

Substances

Antibodies, Monoclonal
daratumumab

Grants and funding

Funding: the authors wish to thank the Norwich Medical School, the United Kingdom National Health Service, the Big C and the Rosetrees Trust for funding, and the Norwich Biorepository (UK) for help with sample collection and storage. pCDH-Lucferase-T2AmCherry was kindly gifted by Prof. Irmela Jeremias, MD, from Helmholtz Zentrum München, Munich, Germany. KMB and SAR receive research funding from Janssen.